Advertisement
Screener

Xilio Therapeutics, Inc. (XLO) Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

Xilio Therapeutics, Inc. Operating Lease Liability

Xilio Therapeutics, Inc. (XLO) had Operating Lease Liability of $6.95 million as of 2025-12-31, per its 10-K filed 2026-03-23.

Financial Statements › Balance Sheet › Liabilities

us-gaap:OperatingLeaseLiability · last filed 2026-03-23

  • 2025-12-31: Operating Lease, Liability $6.95M.
  • 2024-12-31: Operating Lease, Liability $8.14M.
  • 2023-12-31: Operating Lease, Liability $9.19M.
  • 2022-12-31: Operating Lease, Liability $10.11M.
Period endOperating Lease, Liability
2025-12-31$6.95M
10-K · filed 2026-03-23
2024-12-31$8.14M
10-K · filed 2025-03-11
2023-12-31$9.19M
10-K · filed 2024-04-01
2022-12-31$10.11M
10-K · filed 2023-03-02
2021-12-31$10.91M
10-K · filed 2022-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83